SAN DIEGO, March 2, 2025 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio"), a leading biotech company dedicated to developing innovative biologic treatments for allergy, ...
Hosted on MSN
DWTX: Positive interim results for Halneuron® Phase 2b trial in CINP; raising valuation to $15
Positive Interim Results for Phase 2b Trial of Halneuron ® in CINP On December 22, 2025, Dogwood Therapeutics, Inc. (DWTX) announced positive interim results for the Phase 2b HALT-CINP (Halneuron ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback